ClinicalTrials.gg
Active, not recruitingNCT05870124COMFORT 2Updated Mar 4, 2026

Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2)

An interventional study of Nalu Neurostimulation System for PNS and Conventional Medical Management in Peripheral Neuralgia, Peripheral Neuropathy and Chronic Pain, sponsored by Nalu Medical, Inc.. Active, not recruiting at 17 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Nalu Medical, Inc. (part of Boston Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Peripheral Nervous System Diseases with a site in United States — 31 open to participants now, 48 under way, 2 of them phase 3. Peripheral Nervous System Diseases · United States.

Enrollment
23rd of 157
185 · median 43
Started
2023
with 8 others
No phase
91 of 191
19 open now
Primary completion
2025-04
later than 4 of 46 live
Registered
158th of 191
by date

Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, this one is the 23rd largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2023, is one of 91 with no phase, reaches primary completion later than 4 of the 46 other live ones, and was the 158th registered.

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Open to participants now

31 of the 191 studies in Peripheral Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Peripheral Nervous System Diseases with a site in United States, or all of them as a file.
02

Study summary

This post market study is being conducted to document the comparative effectiveness and safety of peripheral nerve stimulation plus conventional medical management versus conventional medical management alone in the treatment of chronic, intractable peripheral neuralgia of post-traumatic or postsurgical origin. This is a prospective, minimal risk, multi-center, randomized control trial.

Read the detailed description

Multi-center, prospective, open-label, randomized controlled trial (RCT) comparing PNS plus CMM with CMM alone. Subjects will be randomized to receive:

Arm 1: Nalu Neurostimulation System for PNS plus CMM Arm 2: CMM alone Consented subjects will receive a baseline evaluation and then be randomized 2:1 into one of two arms: 1) PNS+CMM arm or 2) CMM arm. Subjects assigned to Arm 1 will undergo a trial implant period using best clinical practices. Those subjects who pass the trial implant will receive the permanent implant. At the 3-month end point, subjects in Arm 2 will be given the option to crossover into Arm 1 beginning with a trial implant. All Arm 1 patients receiving a permanent implant will be followed for a total of 36 months after permanent implantation.Arm 2 patients who do not crossover will be followed for a total of 36 months from randomization.

03

Conditions studied

  • Peripheral Neuralgia
  • Peripheral Neuropathy
  • Chronic Pain

Keywords

  • PNS
  • Peripheral nerve stimulation
  • micro-IPG
  • peripheral nerve stimulator
  • chronic pain
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is between 18 to 80 years of age at the time of enrollment.
  2. Subject would have been prescribed PNS therapy regardless of participation in this study; the use of the Nalu device must be on-label.
  3. Subject has been diagnosed with one or more of the conditions listed below in the low back, shoulder, knee, or foot (including ankle):

    • Post-surgical/post-traumatic peripheral neuralgia including but not limited to pain due to peripheral nerve injury, post-surgical scar formation, nerve entrapment
    • Mononeuropathy, specified or unspecified or in diseases classified elsewhere
    • Other neuralgia or neuropathic pain
    • Osteoarthritic pain
  4. Subject has chronic (defined as at least 6 months duration), intractable peripheral neuropathic pain, exclusive of the craniofacial region; any nociceptive pain must be less prominent than the neuropathic pain. Pain should have a predominant neuropathic component as per the investigator's clinical assessment.
  5. Subject should have a pain score of at least 6, in the target area of pain, as recorded on the BPI-Q5 (NRS) at screening.
  6. Subject is willing to cooperate with the study requirements including, compliance with the study procedures and completion of all study visits.
  7. Subject reported stable pain (non-escalating) for 60 days prior to signing .
  8. Subject is currently receiving CMM and has had stable pain medication use and dosage for 30 days prior to signing informed consent.
  9. Subject is psychologically qualified to receive a peripheral nerve stimulator as per the clinician's standard clinical practice and judgment and does not have psychological condition(s) that would interfere with their ability to accurately report outcomes or complete study procedures.
  10. Subject has demonstrated the ability to appropriately place the adhesive clip in the location where the IPG is most likely to be implanted. Alternatively, subject is able to appropriately use the relief belt and/or limb cuff to keep the Therapy Disc in place.

Exclusion criteria

Exclusion Criteria:

Subject currently has an active implantable medical device such as a drug pump, spinal cord stimulator, peripheral nerve stimulator, sacral nerve stimulator, deep brain stimulator, and/or cardiac pacemaker.

2. Subject has previously failed PNS or Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion (DRG) therapy (trial or permanent implant). See note below.

3. Pain is completely absent at rest. 4. Patient has clinical evidence of complex regional pain syndrome (CRPS), peripheral neuralgia of metabolic origin, post-herpetic neuralgia, biochemical evidence of a metabolic or genetic neuropathy (e.g., Charcot'- Marie- Tooth Disease) or mixed motor/sensory polyneuropathy.

5. Subject has a medical condition that would prevent them from participating in the current study per investigator's or medical monitor's judgment.

6. Subject has had a successful (≥ 50% pain relief) interventional procedure within the past 3 months to treat the same pain condition(s) being examined in this study including, nerve blocks.

7. Uncontrolled depression or uncontrolled psychiatric disorders 8. Subject is currently participating in another clinical investigation with an active treatment arm.

9. Subject is allergic or sensitive to materials used in the device components including, skin adhesives or does not tolerate the wearable aspect of the device.

10. Subject has pending or ongoing legal issues (including unresolved worker's compensation claims or equivalent) or other conflicting secondary gain issues related to their chronic pain condition.

11. Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, or progressive peripheral vascular disease that has not been medically corrected.

12. Subject has an active systemic infection. 13. Subject is unable to read and/or write in English or give . 14. Subject has a of less than 1 year. 15. Subject has an active malignant neoplasm ( or local) or evidence of paraneoplastic syndrome.

16. Subject with uncontrolled diabetes mellitus, showing signs of diabetic neuropathy, as evidenced by a neurological exam and a test.

17. Subject has evidence of an alcohol or drug dependency within the last 6 months prior to enrollment.

18. Subject is pregnant (if female and sexually active, subject must be using a reliable form of , be surgically sterile or be at least 1 year ).

19. Subject is nursing/breastfeeding. 20. Subject is on ≥90 mg-morphine equivalents per 24 hours. 21. Subject has undergone an ablative treatment of the target peripheral nerve, or proximal nerve trunk giving rise to the target nerve, or dorsal roots (and DRGs) that ultimately make up the target nerve. No ablative procedures directed at the spinal cord, dorsal roots, or peripheral nerve(s) being treated in the study. To note, subjects who have undergone RF ablation of the dorsal rami, cool pulsed RF of the facet innervation may be considered for enrollment.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
185 participants (actual)

Study arms

  • Active comparator
    PNS Therapy plus Conventional Medical Management (CMM)

    Subjects in this arm will receive a peripheral nerve stimulator and conventional medical management

    Device: Nalu Neurostimulation System for PNS · Other: Conventional Medical Management

  • Active comparator
    Conventional Medical Management

    Subjects will receive only CMM

    Other: Conventional Medical Management

Interventions

  • DeviceNalu Neurostimulation System for PNS

    The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator

    Also known as: Nalu PNS

  • OtherConventional Medical Management

    Conventional Medical Management is the best standard of care treatment for the patient

06

What researchers measure

Primary outcomes

  1. Effectiveness: Responder Rates between the 2 groups

    Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the Numeric Rating Scale (0-10; 0=no pain, 10=worst pain imaginable)

    Time frame: 3-months

  2. Safety: Rate of serious and non-serious device effects

    Rate of serious and non-serious adverse device events between groups

    Time frame: 3-months

Secondary outcomes

  1. Responder Rates

    Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS,0-10 where, 0= no pain; 10=worst pain imaginable).

    Time frame: 6-months,12 months, 24 months and 36-months

  2. Functional Outcomes: Change in Oswestry Disability Index (ODI) score from baseline to protocol defined timepoints

    Change in patient reported ODI from baseline with comparisons between groups. The ODI is scored from 0-100% disability. A lower score, compared to baseline, indicates improvement in ODI.

    Time frame: 3 months, 6-months,12 months, 24 months and 36-months

  3. Functional Outcomes: Change in Beck's Depression Inventory (BDI) score from baseline

    Change in patient reported depression from baseline with comparison between groups. The BDI is scored from 0-63. A lower score at follow-up, compared to baseline, indicates an improvement in depression symptoms and mood.

    Time frame: 3 months, 6-months,12 months, 24 months and 36-months

  4. Functional Outcomes: Patient Global Impression of Change (PGIC)

    PGIC is reported by the patient post-implant, on a 7-point likert scale to indicate overall changes in mood, activity, emotional well-being and quality of life. Proportion of patients showing improvement, worsening or no change, will be collected and reported at protocol specified time points.

    Time frame: 3 months, 6-months,12 months, 24 months and 36-months

  5. Safety Assessment

    Rate of serious and non-serious device effects

    Time frame: 6-months,12 months, 24 months and 36-months

07

Study locations

17 sites
  • The Pain Institute of Southern Arizona
    Tucson, Arizona 85710, United States
  • Comprehensive Spine & Pain Physicians
    Burbank, California 91505, United States
  • Pain Management and Injury Relief
    Thousand Oaks, California 91320, United States
  • DBPS Research LLC
    Denver, Colorado 80111, United States
  • International Spine, Pain & Performance Center
    Washington D.C., District of Columbia 20037, United States
  • Coastal Spine & Pain Center
    Jacksonville, Florida 23305, United States
  • University of Kansas Health System, Bell Hospital Marc A. Asher Comprehensive Spine Center
    Kansas City, Kansas 66160, United States
  • Insight Research Institute
    Flint, Michigan 48507, United States
  • NeuroInterventional Pain Management
    Monroe, Michigan 48161, United States
  • Michigan Neurology & Spine Center
    Port Huron, Michigan 48060, United States
  • Advanced Orthopedics and Sports Medicine Institute
    Freehold, New Jersey 07728, United States
  • The Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Pacific Sports and Spine
    Eugene, Oregon 97401, United States
  • Columbia Pain Management
    Milwaukie, Oregon 97222, United States
  • Pain Specialists of America
    Austin, Texas 78745, United States
  • Institute of Precision Pain Medicine
    Corpus Christi, Texas 78414, United States
  • Anesis Spine and Pain Care
    Spokane, Washington 99216, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Apr 2025, 23 months.

Of 132 interventional studies with no phase under Peripheral Nervous System Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 23, 2023
StartActual
Apr 27, 2023
Primary completionActual
Apr 15, 2025
CompletionEst.
Dec 31, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05870124
Lead sponsor
Nalu Medical, Inc.
Responsible party
Sponsor
First posted
May 23, 2023
Start date
Apr 27, 2023
Primary completion
Apr 15, 2025
Completion
Dec 31, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Patrick Martin
study director · Nalu Medical, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion